TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia
Background In children with intermediate-risk relapsed acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplantation (allo-HSCT) has markedly improved the outcome of patients with an unsatisfactory minimal residual disease (MRD) response. Total body irradiation (TBI), etoposide (ETP), and cyclophosphamide (CY) have been shown to be equivalent to or better than TBI + ETP for conditioning, so we hypothesized that even greater survival could be achieved due to recent advances in HSCT and supportive care. Procedure We prospectively analyzed the efficacy and safety of allo-HSCT with a unified conditioning regimen of TBI + ETP + CY in children with intermediate-risk relapsed ALL, based on MRD in the bone marrow after induction, from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) ALL-R08-II nationwide cohort (UMIN000002025). Results Twenty patients with post-induction MRD ≥ $ 10^{−3} $ and two not evaluated for MRD underwent allo-HSCT. Engraftment was confirmed in all patients, and no transplantation-related mortality was observed. The 3-year event-free survival and overall survival rates after transplantation were 86.4% ± 7.3% and 95.5% ± 4.4%, respectively. Conclusion Allo-HSCT based on post-induction MRD with TBI + ETP + CY conditioning was feasible in Japanese children with intermediate-risk relapsed ALL..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:119 |
|---|---|
| Enthalten in: |
International journal of hematology - 119(2024), 4 vom: 25. Jan., Seite 450-458 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ueki, Hideaki [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Acute lymphoblastic leukemia |
| Anmerkungen: |
© Japanese Society of Hematology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12185-024-03710-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055269699 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055269699 | ||
| 003 | DE-627 | ||
| 005 | 20240325061001.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-024-03710-6 |2 doi | |
| 035 | |a (DE-627)SPR055269699 | ||
| 035 | |a (SPR)s12185-024-03710-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Ueki, Hideaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Japanese Society of Hematology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background In children with intermediate-risk relapsed acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplantation (allo-HSCT) has markedly improved the outcome of patients with an unsatisfactory minimal residual disease (MRD) response. Total body irradiation (TBI), etoposide (ETP), and cyclophosphamide (CY) have been shown to be equivalent to or better than TBI + ETP for conditioning, so we hypothesized that even greater survival could be achieved due to recent advances in HSCT and supportive care. Procedure We prospectively analyzed the efficacy and safety of allo-HSCT with a unified conditioning regimen of TBI + ETP + CY in children with intermediate-risk relapsed ALL, based on MRD in the bone marrow after induction, from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) ALL-R08-II nationwide cohort (UMIN000002025). Results Twenty patients with post-induction MRD ≥ $ 10^{−3} $ and two not evaluated for MRD underwent allo-HSCT. Engraftment was confirmed in all patients, and no transplantation-related mortality was observed. The 3-year event-free survival and overall survival rates after transplantation were 86.4% ± 7.3% and 95.5% ± 4.4%, respectively. Conclusion Allo-HSCT based on post-induction MRD with TBI + ETP + CY conditioning was feasible in Japanese children with intermediate-risk relapsed ALL. | ||
| 650 | 4 | |a Acute lymphoblastic leukemia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Childhood |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Transplantation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Etoposide |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cyclophosphamide |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ogawa, Chitose |4 aut | |
| 700 | 1 | |a Goto, Hiroaki |4 aut | |
| 700 | 1 | |a Nishi, Masanori |4 aut | |
| 700 | 1 | |a Yamanaka, Junko |4 aut | |
| 700 | 1 | |a Mochizuki, Shinji |4 aut | |
| 700 | 1 | |a Nishikawa, Takuro |4 aut | |
| 700 | 1 | |a Kumamoto, Tadashi |4 aut | |
| 700 | 1 | |a Nishiuchi, Ritsuo |4 aut | |
| 700 | 1 | |a Kikuta, Atsushi |4 aut | |
| 700 | 1 | |a Yamamoto, Shohei |4 aut | |
| 700 | 1 | |a Igarashi, Shunji |4 aut | |
| 700 | 1 | |a Sato, Atsushi |4 aut | |
| 700 | 1 | |a Hori, Toshinori |4 aut | |
| 700 | 1 | |a Saito, Akiko M. |4 aut | |
| 700 | 1 | |a Watanabe, Tomoyuki |4 aut | |
| 700 | 1 | |a Deguchi, Takao |4 aut | |
| 700 | 1 | |a Manabe, Atsushi |4 aut | |
| 700 | 1 | |a Horibe, Keizo |4 aut | |
| 700 | 1 | |a Toyoda, Hidemi |0 (orcid)0000-0002-4727-6050 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d Springer Nature Singapore, 1995 |g 119(2024), 4 vom: 25. Jan., Seite 450-458 |w (DE-627)SPR025085697 |w (DE-600)2028991-1 |x 1865-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:119 |g year:2024 |g number:4 |g day:25 |g month:01 |g pages:450-458 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12185-024-03710-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.86 |q VZ |
| 951 | |a AR | ||
| 952 | |d 119 |j 2024 |e 4 |b 25 |c 01 |h 450-458 | ||